Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update

The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs beco...

Full description

Saved in:
Bibliographic Details
Published inHepatology research Vol. 50; no. 8; pp. 892 - 923
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc 01.08.2020
Subjects
antiviral treatment
drug resistance
Hepatitis B
hepatocellular carcinoma
Hepatology
Management
Tenofovir
tenofovir alafenamide
tenofovir disoproxil fumarate
Japan
Online AccessGet full text

Cover

Abstract The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug‐resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.
AbstractList The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug‐resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.
The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug‐resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.
The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug-resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug-resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.
BookMark eNp9kF1LHDEUhoMo1K-b_oJAb0phNJ-T2d61Yt2VFUVb8S7EzIlGZpNpkkH23_hb_GXOutILKZ6bcy6e9-Xw7KDNEAMg9JmSAzrO4T306YByScQG2qaNYhXh4mZzvHlTVzUX9Se0k_MDIVQRJraROzW9CfgqWg9liaPDU-hNiV28W-KTwbfQ-QAZu5hwuQd8ZoK5gwWE8o_1xefnp5_42qch41lwYIuP4TtmhE7w0LemwB7acqbLsP-2d9GfX8e_j6bV_PxkdvRjXlnBhKiYm0ja8EZJUK0DxhVtDBMMJEgu4ZZZZi2FRjrRKmVaUDUT9FaCqzl1IPgu-rru7VP8O0AueuGzha4zAeKQNeMTWZNmUssR_fIOfYhDCuN3mgkuRVMrpUbq25qyKeacwOk--YVJS02JXinXK-X6VfkIk3ew9cWsZJRkfPf_CF1HHn0Hyw_K9fT44nKdeQH1dZWV
CitedBy_id crossref_primary_10_3390_medicina60081334
crossref_primary_10_1111_hepr_13699
crossref_primary_10_2169_internalmedicine_2731_23
crossref_primary_10_1111_hepr_14146
crossref_primary_10_3350_cmh_2022_0420
crossref_primary_10_1055_s_0041_1723088
crossref_primary_10_1111_apt_17765
crossref_primary_10_1111_hepr_13726
crossref_primary_10_1002_jgh3_12737
crossref_primary_10_3390_v16111743
crossref_primary_10_1007_s00535_025_02211_5
crossref_primary_10_1016_j_gastha_2023_06_014
crossref_primary_10_3748_wjg_v27_i43_7497
crossref_primary_10_1007_s40264_024_01399_4
crossref_primary_10_1016_j_ejrad_2022_110461
crossref_primary_10_1111_hepr_14056
crossref_primary_10_1111_hepr_14057
crossref_primary_10_1007_s00432_025_06082_4
crossref_primary_10_14309_ajg_0000000000001157
crossref_primary_10_3350_cmh_2022_0434
crossref_primary_10_7759_cureus_63978
crossref_primary_10_1111_jgh_16590
crossref_primary_10_1111_apt_16788
crossref_primary_10_1002_jmv_26526
crossref_primary_10_1016_j_jhep_2021_07_002
crossref_primary_10_1111_hepr_14016
crossref_primary_10_1002_jgh3_13067
crossref_primary_10_1111_hepr_13761
crossref_primary_10_1111_jvh_13869
crossref_primary_10_1016_j_jtct_2024_01_059
crossref_primary_10_1111_cen3_12721
crossref_primary_10_1111_jvh_13740
crossref_primary_10_1371_journal_pone_0263844
crossref_primary_10_30683_1929_2279_2022_11_11
crossref_primary_10_1016_j_jiac_2021_06_009
crossref_primary_10_1111_trf_17390
crossref_primary_10_3390_ijms22031456
crossref_primary_10_1097_HEP_0000000000000037
crossref_primary_10_1371_journal_pone_0261760
crossref_primary_10_1111_hepr_14084
crossref_primary_10_3390_v17010044
crossref_primary_10_1111_hepr_14129
crossref_primary_10_1111_liv_16029
crossref_primary_10_1007_s00535_022_01872_w
crossref_primary_10_1111_jvh_13912
crossref_primary_10_1111_ctr_15389
crossref_primary_10_1159_000541293
crossref_primary_10_1016_S2468_1253_23_00197_8
crossref_primary_10_1111_liv_15065
crossref_primary_10_3390_ijms222011051
crossref_primary_10_4254_wjh_v16_i11_1321
crossref_primary_10_1002_jgh3_12950
crossref_primary_10_1007_s00535_020_01748_x
crossref_primary_10_1016_j_jiac_2023_09_007
crossref_primary_10_3390_v16040529
crossref_primary_10_3350_cmh_2024_0780
crossref_primary_10_1002_poh2_30
crossref_primary_10_1093_mr_road098
crossref_primary_10_20340_vmi_rvz_2024_4_CLIN_4
crossref_primary_10_1007_s12328_021_01423_5
crossref_primary_10_1007_s00535_023_02046_y
crossref_primary_10_3904_kjm_2022_97_6_353
crossref_primary_10_3390_jcm11020387
crossref_primary_10_1371_journal_pone_0261878
crossref_primary_10_1007_s40121_023_00795_0
crossref_primary_10_1007_s12328_024_02078_8
crossref_primary_10_1038_s41598_021_03706_w
crossref_primary_10_1016_j_jfma_2023_05_029
crossref_primary_10_2957_kanzo_65_318
crossref_primary_10_1007_s00535_021_01826_8
crossref_primary_10_1111_hepr_13864
crossref_primary_10_1248_bpb_b23_00907
crossref_primary_10_1111_jvh_13805
crossref_primary_10_1111_hepr_14036
crossref_primary_10_3390_livers4030026
crossref_primary_10_1002_jmv_28210
crossref_primary_10_1002_jmv_28452
crossref_primary_10_1016_j_eclinm_2024_103038
crossref_primary_10_1111_hepr_13815
crossref_primary_10_1016_j_eclinm_2024_103039
crossref_primary_10_3389_fpubh_2023_1137738
crossref_primary_10_1016_j_aohep_2024_101764
crossref_primary_10_3892_wasj_2021_87
crossref_primary_10_3390_diagnostics11071262
crossref_primary_10_1007_s40121_024_00997_0
crossref_primary_10_3390_ijms25042245
crossref_primary_10_1111_jgh_15563
crossref_primary_10_1093_cid_ciad506
Cites_doi 10.1053/j.gastro.2013.12.028
10.7326/0003-4819-118-3-199302010-00006
10.1111/hepr.12117
10.1002/hep.22106
10.1053/j.gastro.2006.04.015
10.1111/j.1872-034X.2012.00998.x
10.2957/kanzo.50.38
10.1200/JCO.2008.18.0182
10.1179/102453309X385223
10.1016/j.jhep.2009.12.036
10.1016/0016-5085(95)90401-8
10.1055/s-2006-939751
10.1002/hep.20956
10.1016/S2468-1253(16)30024-3
10.1016/j.jcv.2011.06.020
10.1002/hep.27950
10.1016/j.jhep.2017.11.039
10.1016/0168-8278(91)90031-6
10.1007/s12072-008-9080-3
10.1016/j.jhep.2007.07.022
10.1016/j.jhep.2011.11.030
10.1053/j.gastro.2003.09.026
10.1111/j.1600-0676.1984.tb00942.x
10.3748/wjg.v18.i22.2850
10.1111/jvh.12840
10.1111/hepr.12108
10.1136/annrheumdis-2016-209973
10.1182/blood-2003-05-1403
10.1111/hepr.12842
10.1136/gutjnl-2014-308353
10.1086/590968
10.1002/jmv.20981
10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0
10.1016/j.jhep.2012.02.010
10.1001/jama.2014.15704
10.1111/j.1872-034X.2007.00094.x
10.1016/j.jcv.2004.10.006
10.1111/j.1872-034X.2011.00910.x
10.1002/hep.1840070106
10.3324/haematol.2009.008607
10.1056/NEJMoa013215
10.1016/j.jhep.2008.02.019
10.1097/00007890-199809150-00012
10.7326/0003-4819-135-9-200111060-00006
10.1016/0016-5085(88)90623-3
10.1111/hepr.12578
10.1002/hep.510280241
10.1016/0016-5085(91)90599-G
10.1016/S0168-8278(01)00266-5
10.1016/S0140-6736(88)92355-0
10.1016/j.transproceed.2010.05.127
10.1177/135965350501000612
10.7326/0003-4819-148-7-200804010-00008
10.1053/jhep.2001.27834
10.1111/hepr.12902
10.1002/hep.21077
10.1002/hep.23190
10.1073/pnas.88.10.4186
10.1111/hepr.12269
10.1053/j.gastro.2005.11.016
10.1002/jmv.21339
10.1016/S0016-5085(83)80114-0
10.1056/NEJM199008023230503
10.1136/gut.2010.223206
10.1053/j.gastro.2009.08.063
10.1002/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q
10.1007/s00535-016-1168-2
10.1136/gutjnl-2014-308435
10.1002/hep.1840060203
10.1002/hep.510310130
10.1093/ndt/16.11.2222
10.1053/gast.2002.35352
10.1111/hepr.12513
10.1016/j.jhep.2009.11.007
10.1086/653209
10.1002/jmv.20546
10.1007/s12072-008-9068-z
10.1016/j.jhep.2008.07.040
10.1002/hep.22878
10.1002/hep.21723
10.1016/j.jcv.2016.02.026
10.1038/sj.bmt.1700744
10.2147/DDDT.S65349
10.7326/0003-4819-94-6-744
10.3109/s10165-010-0337-z
10.1093/cid/civ474
10.3899/jrheum.100692
10.1007/s00535-010-0367-5
10.1136/ard.2005.043257
10.1002/hep.26718
10.1111/j.1872-034X.2011.00937.x
10.1038/sj.bmt.1703614
10.1016/0016-5085(92)90337-X
10.1002/hep.1840030309
10.1016/0016-5085(91)70034-U
10.1093/jnci/dji043
10.1182/blood-2018-10-878892
10.1097/00007890-199802270-00007
10.1056/NEJMoa033364
10.1182/blood-2018-04-848044
10.3748/wjg.v18.i21.2661
10.1111/jgh.12499
10.1016/0016-5085(93)90281-G
10.3960/jslrt.52.67
10.1016/0016-5085(94)90557-6
10.1517/14740331003627458
10.1111/j.1600-6143.2006.01542.x
10.1016/j.jhep.2006.08.021
10.7326/0003-4819-121-4-199408150-00007
10.1093/cid/civ344
10.1111/j.1600-0609.2009.01291.x
10.1016/0168-8278(90)90069-4
10.1007/s005350170143
10.1002/hep.510300221
10.1128/AAC.48.9.3498-3507.2004
10.1001/jama.295.1.65
10.1016/j.hepres.2006.08.005
10.1007/s005350200155
10.1023/B:CACO.0000007984.79987.ec
10.1200/JCO.2004.05.161
10.1056/NEJMoa1007644
10.1159/000122592
10.1053/jhep.2002.34294
10.3851/IMP2294
10.1016/S0140-6736(87)91371-7
10.1038/sj.bjc.6601699
10.1038/ajg.2011.302
10.1016/0016-5085(87)90613-5
10.1111/liv.13496
10.1002/hep.23346
10.1002/hep.23785
10.1128/JCM.00366-07
10.1053/jhep.2002.33638
10.1002/hep.23246
10.1177/135965350701200309
10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
10.1016/S0168-8278(02)00004-1
10.1097/BOR.0b013e3282f05b63
10.1111/j.1600-0609.2004.00375.x
10.1016/j.ejca.2013.07.006
10.3748/wjg.v20.i11.2955
10.1002/hep.510300313
10.1016/j.cld.2010.05.007
10.1016/S2468-1253(16)30107-8
10.1016/j.jhep.2007.11.011
10.1002/jmv.23513
10.3851/IMP1304
10.1111/hepr.12919
10.1016/S0168-8278(00)80371-2
10.1016/0016-5085(84)90406-2
10.1002/hep.24361
10.1053/jhep.2002.35068
ContentType Journal Article
Copyright 2020 The Japan Society of Hepatology
2020 The Japan Society of Hepatology.
Copyright_xml – notice: 2020 The Japan Society of Hepatology
– notice: 2020 The Japan Society of Hepatology.
CorporateAuthor Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
CorporateAuthor_xml – name: Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
DBID AAYXX
CITATION
7T5
7TM
7U9
H94
7X8
DOI 10.1111/hepr.13504
DatabaseName CrossRef
Immunology Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList
AIDS and Cancer Research Abstracts
MEDLINE - Academic
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1872-034X
EndPage 923
ExternalDocumentID 10_1111_hepr_13504
HEPR13504
Genre article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
--K
.3N
.GA
.Y3
05W
0R~
10A
1B1
1OC
1~5
29I
31~
33P
3SF
4.4
4G.
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AALRI
AAMNL
AANHP
AANLZ
AAONW
AAQFI
AAQXK
AASGY
AAXRX
AAXUO
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIUM
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITUG
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
ESX
EX3
F00
F01
F04
F5P
FDB
FEDTE
FGOYB
FUBAC
G-Q
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NQ-
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
R2-
RIG
ROL
RPZ
RX1
SEW
SSZ
SUPJJ
TEORI
TUS
UB1
UHS
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
ZZTAW
~IA
~WT
AAYXX
ACVFH
ADCNI
AEUPX
AEYWJ
AFPUW
AGHNM
AGQPQ
AGYGG
AIGII
CITATION
7T5
7TM
7U9
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
H94
7X8
ID FETCH-LOGICAL-c4244-2f95183875e7dfe23718a242e5e535eb2c2cc1e85f4d77ade76241b5ef631fe43
IEDL.DBID DR2
ISSN 1386-6346
IngestDate Fri Jul 11 12:15:50 EDT 2025
Fri Jul 25 06:20:46 EDT 2025
Tue Jul 01 01:58:22 EDT 2025
Thu Apr 24 22:59:16 EDT 2025
Wed Jan 22 16:37:25 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4244-2f95183875e7dfe23718a242e5e535eb2c2cc1e85f4d77ade76241b5ef631fe43
Notes Drafting Committee for Hepatitis Management Guidelines (in alphabetical order): Ryoichi Ando, Department of Nephrology, Musashino Red Cross Hospital (appointed by the Japanese Society for Dialysis Therapy); Yasuhiro Asahina, Department of Gastroenterology and Hepatology, School of Medicine/Department of Liver Disease Control, Graduate School of Medical and Dental Sciences; Tokyo Medical and Dental University; Kazuaki Chayama*, Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University Naoki Hiramatsu Department of Gastroenterology, Osaka Rosai Hospital; Toru Ikegami Department of Surgery and Science, Kyushu University; Namiki Izumi, Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital; Kan Kikuchi, Department of Nephrology, Shimoochiai Clinic (appointed by the Japanese Society for Dialysis Therapy); Kazuhiko Koike Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo Masayuki Kurosaki Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital; Satoshi Mochida Department of Gastroenterology and Hepatology, Saitama Medical University; Fumitaka Suzuki,Department ofHepatology, Toranomon Hospital; Tetsuo Takehara*, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine; Hajime Takikawa**, Department of Medicine, Teikyo University School of Medicine; Atsushi Tanaka, Department of Medicine, Teikyo University School of Medicine Eiji Tanaka Department for the Promotion of Regional Medicine, Shinshu University School of Medicine; Yasuhito Tanaka, Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences; Hiroshi Yotsuyanagi, Department of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo (*Special Committee Member; **Committee Chair)
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PQID 2435486777
PQPubID 2045151
PageCount 923
ParticipantIDs proquest_miscellaneous_2395608965
proquest_journals_2435486777
crossref_primary_10_1111_hepr_13504
crossref_citationtrail_10_1111_hepr_13504
wiley_primary_10_1111_hepr_13504_HEPR13504
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2020
PublicationDateYYYYMMDD 2020-08-01
PublicationDate_xml – month: 08
  year: 2020
  text: August 2020
PublicationDecade 2020
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
PublicationTitle Hepatology research
PublicationYear 2020
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2004; 22
2010; 14
2009; 81
1991; 13
1983; 3
2009; 83
2011; 60
2006; 36
2006; 295
2011; 52
2011; 54
2012; 18
2014; 29
2001; 44
2007; 79
2018; 48
1996; 78
2014; 20
2001; 135
2009; 14
2013; 58
1991; 100
2000; 14
2009; 94
1991; 88
2017; 76
1986; 6
2006; 26
2005; 74
2018; 38
2011; 364
2016; 46
2010; 9
2007; 19
1991; 78
2010; 202
2004; 48
2013; 85
1988; 94
2008; 51
1998; 65
1993; 104
2007; 12
2014; 312
2014; 44
1998; 66
2018; 26
2018; 25
2010; 42
1993; 118
2016; 1
1984; 4
2006; 43
2015; 62
2015; 61
2002; 123
2008; 47
2008; 48
1983; 84
2005; 97
2005; 10
1999; 30
1981; 94
2001; 34
2003; 102
2001; 36
2010; 52
2010; 51
2012; 42
2014; 146
1987; 2
1990; 10
2006; 78
2017; 47
1987; 7
2006; 130
2003; 14
2006; 131
2008; 148
2012; 57
2008; 2
2009; 49
2007; 37
2012; 52
2016; 78
2013; 18
2015; 45
2009; 50
2006; 65
1997; 19
2000; 62
2014; 59
2002; 347
2005; 32
2011; 21
2001; 16
2014; 8
2003; 125
1994; 107
2002; 36
1984; 86
2002; 37
1998; 28
1990; 323
2013; 49
2012
2002; 30
2011
1987; 92
2013; 40
1992; 102
2002; 35
2009
2006; 6
2016; 51
2004; 90
2011; 38
2009; 27
2009; 137
1998; 25
2018; 68
1988; 2
1994; 121
2004; 351
2011; 106
2000; 33
1995; 109
2000; 31
2016; 65
2016
2011; 46
2014
2007; 45
2007; 46
2019; 133
2007; 47
e_1_2_10_44_1
e_1_2_10_40_1
e_1_2_10_131_1
Noguchi Y (e_1_2_10_154_1) 2013; 40
e_1_2_10_158_1
e_1_2_10_70_1
e_1_2_10_93_1
e_1_2_10_2_1
e_1_2_10_139_1
e_1_2_10_18_1
e_1_2_10_74_1
e_1_2_10_97_1
e_1_2_10_116_1
e_1_2_10_150_1
e_1_2_10_6_1
e_1_2_10_55_1
e_1_2_10_135_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_78_1
e_1_2_10_112_1
e_1_2_10_13_1
e_1_2_10_32_1
e_1_2_10_51_1
e_1_2_10_120_1
e_1_2_10_147_1
e_1_2_10_82_1
e_1_2_10_128_1
e_1_2_10_29_1
e_1_2_10_63_1
e_1_2_10_105_1
e_1_2_10_124_1
e_1_2_10_162_1
e_1_2_10_25_1
e_1_2_10_48_1
e_1_2_10_67_1
e_1_2_10_101_1
e_1_2_10_143_1
e_1_2_10_45_1
e_1_2_10_22_1
e_1_2_10_41_1
e_1_2_10_132_1
e_1_2_10_155_1
e_1_2_10_159_1
e_1_2_10_90_1
e_1_2_10_71_1
e_1_2_10_117_1
e_1_2_10_94_1
e_1_2_10_52_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_75_1
e_1_2_10_113_1
e_1_2_10_136_1
e_1_2_10_151_1
e_1_2_10_38_1
e_1_2_10_98_1
e_1_2_10_56_1
e_1_2_10_79_1
Urata Y (e_1_2_10_152_1) 2018; 26
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_121_1
e_1_2_10_144_1
e_1_2_10_148_1
e_1_2_10_60_1
e_1_2_10_106_1
e_1_2_10_129_1
e_1_2_10_83_1
e_1_2_10_64_1
e_1_2_10_102_1
e_1_2_10_125_1
e_1_2_10_140_1
e_1_2_10_163_1
e_1_2_10_49_1
e_1_2_10_87_1
e_1_2_10_26_1
e_1_2_10_68_1
e_1_2_10_23_1
e_1_2_10_46_1
e_1_2_10_69_1
e_1_2_10_42_1
e_1_2_10_110_1
e_1_2_10_156_1
e_1_2_10_91_1
Lai CL (e_1_2_10_21_1) 1991; 78
e_1_2_10_72_1
e_1_2_10_95_1
e_1_2_10_118_1
e_1_2_10_4_1
e_1_2_10_53_1
e_1_2_10_137_1
e_1_2_10_16_1
e_1_2_10_39_1
e_1_2_10_76_1
e_1_2_10_99_1
Qi X (e_1_2_10_86_1) 2007; 12
e_1_2_10_114_1
e_1_2_10_8_1
e_1_2_10_57_1
e_1_2_10_133_1
e_1_2_10_58_1
e_1_2_10_34_1
e_1_2_10_11_1
e_1_2_10_30_1
e_1_2_10_119_1
e_1_2_10_145_1
e_1_2_10_80_1
e_1_2_10_149_1
e_1_2_10_61_1
e_1_2_10_84_1
e_1_2_10_107_1
e_1_2_10_160_1
e_1_2_10_27_1
e_1_2_10_65_1
e_1_2_10_88_1
e_1_2_10_103_1
e_1_2_10_141_1
e_1_2_10_122_1
e_1_2_10_164_1
e_1_2_10_24_1
Hagiyama H (e_1_2_10_109_1) 2004; 22
e_1_2_10_43_1
Terrault N (e_1_2_10_126_1) 2000; 14
e_1_2_10_20_1
e_1_2_10_130_1
e_1_2_10_157_1
Narvaez J (e_1_2_10_108_1) 1998; 25
e_1_2_10_92_1
e_1_2_10_73_1
e_1_2_10_115_1
e_1_2_10_138_1
e_1_2_10_96_1
e_1_2_10_54_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_77_1
e_1_2_10_111_1
e_1_2_10_134_1
e_1_2_10_153_1
e_1_2_10_36_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_59_1
e_1_2_10_31_1
e_1_2_10_50_1
Marcellin P (e_1_2_10_12_1) 2013; 58
e_1_2_10_146_1
e_1_2_10_81_1
e_1_2_10_62_1
e_1_2_10_104_1
e_1_2_10_127_1
e_1_2_10_161_1
e_1_2_10_85_1
e_1_2_10_28_1
e_1_2_10_66_1
e_1_2_10_100_1
e_1_2_10_123_1
e_1_2_10_142_1
e_1_2_10_165_1
e_1_2_10_47_1
e_1_2_10_89_1
References_xml – year: 2011
– volume: 45
  start-page: 1363
  year: 2015
  end-page: 1367
  article-title: Fatal reactivation of hepatitis B virus infection in a patient with adult T‐cell leukemia‐lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab
  publication-title: Hepatol Res
– volume: 36
  start-page: 272
  year: 2006
  end-page: 276
  article-title: Measurement of hepatitis B virus core‐related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection
  publication-title: Hepatol Res
– volume: 14
  start-page: 39
  issue: Suppl 2
  year: 2000
  end-page: 43
  article-title: Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges
  publication-title: Clin Transplant
– volume: 7
  start-page: 20
  year: 1987
  end-page: 23
  article-title: Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody‐positive patients
  publication-title: Hepatology
– volume: 52
  start-page: 886
  year: 2010
  end-page: 893
  article-title: Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
  publication-title: Hepatology
– volume: 65
  start-page: 1042
  year: 2016
  end-page: 1051
  article-title: Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir‐resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial
  publication-title: Gut
– volume: 47
  start-page: e52
  year: 2008
  end-page: e56
  article-title: Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan
  publication-title: Clin Infect Dis
– volume: 40
  start-page: 1561
  year: 2013
  end-page: 1563
  article-title: A case of hepatitis B virus reactivation in a patient with prior resolved hepatitis B infection during bevacizumab plus FOLFIRI treatment
  publication-title: Gan To Kagaku Ryoho
– volume: 51
  start-page: 73
  year: 2010
  end-page: 80
  article-title: Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues
  publication-title: Hepatology
– volume: 18
  start-page: 2661
  year: 2012
  end-page: 2667
  article-title: Family history influences the early onset of hepatocellular carcinoma
  publication-title: World J Gastroenterol
– volume: 49
  start-page: 1859
  year: 2009
  end-page: 1867
  article-title: Long‐term outcome of hepatitis B e antigen‐negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time
  publication-title: Hepatology
– volume: 102
  start-page: 2091
  year: 1992
  end-page: 2097
  article-title: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
  publication-title: Gastroenterology
– volume: 14
  start-page: 73
  year: 2009
  end-page: 75
  article-title: Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft‐versus‐host disease
  publication-title: Hematology
– volume: 50
  start-page: 661
  year: 2009
  end-page: 662
  article-title: Chronic hepatitis B: update 2009
  publication-title: Hepatology
– volume: 48
  start-page: 923
  year: 2008
  end-page: 931
  article-title: Low risk of adefovir resistance in lamivudine‐resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two‐year follow‐up
  publication-title: J Hepatol
– volume: 14
  start-page: 873
  year: 2009
  end-page: 877
  article-title: Two types of drug‐resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir
  publication-title: Antivir Ther
– volume: 50
  start-page: 426
  year: 2009
  end-page: 431
  article-title: Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure
  publication-title: J Hepatol
– volume: 2
  start-page: 185
  year: 2008
  end-page: 189
  article-title: infection with persistently normal ALT b. not to treat
  publication-title: Hepatol Int
– volume: 76
  start-page: 1051
  year: 2017
  end-page: 1056
  article-title: Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan
  publication-title: Ann Rheum Dis
– volume: 37
  start-page: 922
  year: 2002
  end-page: 927
  article-title: Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long‐term lamivudine therapy
  publication-title: J Gastroenterol
– volume: 52
  start-page: 67
  year: 2012
  end-page: 69
  article-title: Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report
  publication-title: J Clin Exp Hematop
– year: 2014
– volume: 27
  start-page: 605
  year: 2009
  end-page: 611
  article-title: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab
  publication-title: J Clin Oncol
– volume: 38
  start-page: 76
  year: 2018
  end-page: 83
  article-title: Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct‐acting antiviral treatment for HCV
  publication-title: Liver Int
– volume: 92
  start-page: 1839
  year: 1987
  end-page: 1843
  article-title: Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
  publication-title: Gastroenterology
– volume: 10
  start-page: 727
  year: 2005
  end-page: 734
  article-title: Selection of hepatitis B virus polymerase mutations in HIV‐coinfected patients treated with tenofovir
  publication-title: Antivir Ther
– volume: 46
  start-page: 556
  year: 2011
  end-page: 564
  article-title: Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg‐positive and HBsAg‐negative cohorts
  publication-title: J Gastroenterol
– volume: 57
  start-page: 196
  year: 2012
  end-page: 202
  article-title: Follow‐up and indications for liver biopsy in HBeAg‐negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review
  publication-title: J Hepatol
– volume: 44
  start-page: 354
  year: 2014
  end-page: 357
  article-title: Reactivation of hepatitis B virus in a patient with adult T‐cell leukemia‐lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab
  publication-title: Hepatol Res
– volume: 84
  start-page: 216
  year: 1983
  end-page: 219
  article-title: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis
  publication-title: Gastroenterology
– volume: 102
  start-page: 1930
  year: 2003
  article-title: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy
  publication-title: Blood
– volume: 19
  start-page: 795
  year: 1997
  end-page: 799
  article-title: Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study
  publication-title: Bone Marrow Transplant
– volume: 323
  start-page: 295
  year: 1990
  end-page: 301
  article-title: A randomized, controlled trial of interferon alfa‐2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group
  publication-title: N Engl J Med
– volume: 59
  start-page: 2092
  year: 2014
  end-page: 2100
  article-title: Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study
  publication-title: Hepatology
– volume: 100
  start-page: 1432
  year: 1991
  end-page: 1434
  article-title: Redevelopment of hepatitis B surface antigen after renal transplantation
  publication-title: Gastroenterology
– volume: 20
  start-page: 2955
  year: 2014
  end-page: 2961
  article-title: Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection
  publication-title: World J Gastroenterol
– volume: 36
  start-page: 263
  year: 2002
  end-page: 270
  article-title: Outcome of anti‐HBe positive chronic hepatitis B in alpha‐interferon treated and untreated patients: a long term cohort study
  publication-title: J Hepatol
– volume: 94
  start-page: 151
  year: 1988
  end-page: 156
  article-title: Hepatitis B virus and hepatitis B‐related viral infection in renal transplant recipients. A prospective study of 90 patients
  publication-title: Gastroenterology
– volume: 78
  start-page: 27
  year: 2016
  end-page: 30
  article-title: Direct‐acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge
  publication-title: J Clin Virol
– volume: 202
  start-page: 86
  year: 2010
  end-page: 92
  article-title: HBsAg profiles in patients receiving peginterferon alfa‐2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
  publication-title: J Infect Dis
– volume: 46
  start-page: 45
  year: 2007
  end-page: 52
  article-title: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
  publication-title: J Hepatol
– volume: 3
  start-page: 330
  year: 1983
  end-page: 336
  article-title: Natural history of hepatitis B virus infection in renal transplant recipients‐‐a fifteen‐year follow‐up
  publication-title: Hepatology
– volume: 26
  start-page: 51
  year: 2018
  end-page: 56
  article-title: Reactivation of hepatitis B
  publication-title: Inflammation & Immunity [in Japanese]
– volume: 78
  start-page: 155
  year: 1991
  end-page: 163
  article-title: Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children
  publication-title: Q J Med
– volume: 13
  start-page: S82
  issue: Suppl 4
  year: 1991
  end-page: S86
  article-title: 'e' antigen defective hepatitis B virus and course of chronic infection
  publication-title: J Hepatol
– volume: 1
  start-page: 196
  year: 2016
  end-page: 206
  article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg‐negative chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial
  publication-title: Lancet Gastroenterol Hepatol
– volume: 78
  start-page: 2210
  year: 1996
  end-page: 2215
  article-title: Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991
  publication-title: Cancer
– volume: 43
  start-page: S173
  year: 2006
  end-page: S181
  article-title: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005
  publication-title: Hepatology
– volume: 22
  start-page: 375
  year: 2004
  end-page: 376
  article-title: follow in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low‐dose methotrexate therapy for rheumatoid arthritis
  publication-title: Clin Exp Rheumatol
– volume: 10
  start-page: 29
  year: 1990
  end-page: 34
  article-title: Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology
  publication-title: J Hepatol
– volume: 14
  start-page: 995
  year: 2003
  end-page: 1000
  article-title: Spontaneous clearance of high‐titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population
  publication-title: Cancer Causes Control
– volume: 9
  start-page: 545
  year: 2010
  end-page: 559
  article-title: Renal toxicity associated with tenofovir use
  publication-title: Expert Opin Drug Saf
– volume: 137
  start-page: 1593
  year: 2009
  end-page: 1608
  article-title: Hepatitis B virus resistance to nucleos(t)ide analogues
  publication-title: Gastroenterology
– volume: 107
  start-page: 1514
  year: 1994
  end-page: 1518
  article-title: Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation
  publication-title: Gastroenterology
– volume: 36
  start-page: 702
  year: 2002
  end-page: 709
  article-title: Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
  publication-title: Hepatology
– volume: 61
  start-page: 1304
  year: 2015
  end-page: 1306
  article-title: Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir
  publication-title: Clin Infect Dis
– volume: 36
  start-page: 543
  year: 2002
  end-page: 546
  article-title: Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers
  publication-title: J Hepatol
– volume: 46
  start-page: 388
  year: 2007
  end-page: 394
  article-title: Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis
  publication-title: Hepatology
– volume: 45
  start-page: 3942
  year: 2007
  end-page: 3947
  article-title: Hepatitis B virus core‐related antigens as markers for monitoring chronic hepatitis B infection
  publication-title: J Clin Microbiol
– volume: 51
  start-page: 999
  year: 2016
  end-page: 1010
  article-title: Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies
  publication-title: J Gastroenterol
– volume: 133
  start-page: 498
  year: 2019
  end-page: 501
  article-title: Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced‐stage DLBCL
  publication-title: Blood
– volume: 146
  start-page: 980
  year: 2014
  end-page: 988
  article-title: Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine‐resistant chronic hepatitis B
  publication-title: Gastroenterology
– volume: 6
  start-page: 2680
  year: 2006
  end-page: 2685
  article-title: Beneficial effects of short‐term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation
  publication-title: Am J Transplant
– volume: 65
  start-page: 983
  year: 2006
  end-page: 989
  article-title: Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies
  publication-title: Ann Rheum Dis
– year: 2016
– volume: 47
  start-page: 1032
  year: 2017
  end-page: 1041
  article-title: Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs
  publication-title: Hepatol Res
– volume: 90
  start-page: 1306
  year: 2004
  end-page: 1311
  article-title: Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy
  publication-title: Br J Cancer
– volume: 133
  start-page: 137
  year: 2019
  end-page: 146
  article-title: Risk of HBV reactivation in patients with B‐cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy
  publication-title: Blood
– volume: 44
  start-page: 1
  issue: Suppl S1
  year: 2014
  end-page: 58
  article-title: JSH Guidelines for the Management of Hepatitis B Virus Infection
  publication-title: Hepatol Res
– volume: 14
  start-page: 381
  year: 2010
  end-page: 396
  article-title: Natural history of chronic hepatitis B
  publication-title: Clin Liver Dis
– volume: 62
  start-page: 932
  year: 2015
  end-page: 954
  article-title: Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
  publication-title: Hepatology
– volume: 47
  start-page: 760
  year: 2007
  end-page: 767
  article-title: The clinical significance of persistently normal ALT in chronic hepatitis B infection
  publication-title: J Hepatol
– volume: 28
  start-page: 585
  year: 1998
  end-page: 589
  article-title: Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
  publication-title: Hepatology
– volume: 125
  start-page: 1742
  year: 2003
  end-page: 1749
  article-title: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
  publication-title: Gastroenterology
– volume: 60
  start-page: 247
  year: 2011
  end-page: 254
  article-title: Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
  publication-title: Gut
– volume: 1
  start-page: 185
  year: 2016
  end-page: 195
  article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg‐positive chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial
  publication-title: Lancet Gastroenterol Hepatol
– volume: 65
  start-page: 494
  year: 1998
  end-page: 499
  article-title: Transmission of hepatitis B virus from hepatitis B core antibody‐positive donors in living related liver transplants
  publication-title: Transplantation
– volume: 35
  start-page: 1522
  year: 2002
  end-page: 1527
  article-title: Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
  publication-title: Hepatology
– volume: 37
  start-page: 661
  year: 2007
  end-page: 666
  article-title: Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy
  publication-title: Hepatol Res
– volume: 42
  start-page: 627
  year: 2012
  end-page: 636
  article-title: Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
  publication-title: Hepatol Res
– volume: 57
  start-page: 167
  year: 2012
  end-page: 185
  article-title: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection
  publication-title: J Hepatol
– volume: 54
  start-page: 91
  year: 2011
  end-page: 100
  article-title: Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open‐label study
  publication-title: Hepatology
– volume: 295
  start-page: 65
  year: 2006
  end-page: 73
  article-title: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
  publication-title: JAMA
– volume: 42
  start-page: 3167
  year: 2010
  end-page: 3168
  article-title: Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post‐liver transplant
  publication-title: Transplant Proc
– volume: 43
  start-page: 556
  year: 2006
  end-page: 562
  article-title: Chronic hepatitis B in children after e antigen seroclearance: final report of a 29‐year longitudinal study
  publication-title: Hepatology
– volume: 86
  start-page: 230
  year: 1984
  end-page: 235
  article-title: Spontaneous reactivation of chronic hepatitis B virus infection
  publication-title: Gastroenterology
– volume: 44
  start-page: 1
  year: 2014
  end-page: 8
  article-title: Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B
  publication-title: Hepatol Res
– volume: 97
  start-page: 265
  year: 2005
  end-page: 272
  article-title: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men
  publication-title: J Natl Cancer Inst
– volume: 19
  start-page: 619
  year: 2007
  end-page: 625
  article-title: Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co‐existing chronic viral infections
  publication-title: Curr Opin Rheumatol
– volume: 48
  start-page: 59
  year: 2018
  end-page: 68
  article-title: Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naive chronic hepatitis B patients
  publication-title: Hepatol Res
– year: 2009
– volume: 123
  start-page: 719
  year: 2002
  end-page: 727
  article-title: Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy
  publication-title: Gastroenterology
– volume: 44
  start-page: 339
  year: 2001
  end-page: 342
  article-title: Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low‐dose methotrexate therapy in a rheumatoid arthritis patient
  publication-title: Arthritis Rheum
– volume: 50
  start-page: 2001
  year: 2009
  end-page: 2006
  article-title: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function
  publication-title: Hepatology
– volume: 48
  start-page: 335
  year: 2008
  end-page: 352
  article-title: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors
  publication-title: J Hepatol
– volume: 58
  start-page: 649A
  year: 2013
  article-title: Seven years of treatment with tenofovir df for chronic hepatitis b virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance
  publication-title: Hepatology
– volume: 364
  start-page: 236
  year: 2011
  end-page: 247
  article-title: Nucleic acid testing to detect HBV infection in blood donors
  publication-title: N Engl J Med
– volume: 104
  start-page: 1116
  year: 1993
  end-page: 1121
  article-title: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B
  publication-title: Gastroenterology
– volume: 25
  start-page: 608
  year: 2018
  end-page: 611
  article-title: Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct‐acting antiviral therapy
  publication-title: J Viral Hepat
– volume: 52
  start-page: 151
  year: 2011
  end-page: 154
  article-title: Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection
  publication-title: J Clin Virol
– volume: 16
  start-page: 2222
  year: 2001
  end-page: 2228
  article-title: Outcome of renal transplantation in hepatitis B surface antigen‐positive patients after introduction of lamivudine
  publication-title: Nephrol Dial Transplant
– volume: 31
  start-page: 207
  year: 2000
  end-page: 210
  article-title: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
  publication-title: Hepatology
– volume: 66
  start-page: 616
  year: 1998
  end-page: 619
  article-title: Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti‐HBs and anti‐HBc
  publication-title: Transplantation
– volume: 34
  start-page: 617
  year: 2001
  end-page: 624
  article-title: Hepatitis B e antigen‐negative chronic hepatitis B
  publication-title: Hepatology
– volume: 52
  start-page: 791
  year: 2010
  end-page: 799
  article-title: Long‐term use of entecavir in nucleoside‐naive Japanese patients with chronic hepatitis B infection
  publication-title: J Hepatol
– volume: 100
  start-page: 182
  year: 1991
  end-page: 188
  article-title: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study
  publication-title: Gastroenterology
– volume: 68
  start-page: 672
  year: 2018
  end-page: 681
  article-title: 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
  publication-title: J Hepatol
– volume: 131
  start-page: 59
  year: 2006
  end-page: 68
  article-title: Kinetics and risk of de novo hepatitis B infection in HBsAg‐negative patients undergoing cytotoxic chemotherapy
  publication-title: Gastroenterology
– volume: 26
  start-page: 130
  year: 2006
  end-page: 141
  article-title: Hepatitis B e antigen‐negative chronic hepatitis B: natural history and treatment
  publication-title: Semin Liver Dis
– volume: 312
  start-page: 2521
  year: 2014
  end-page: 2530
  article-title: Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B‐cell lymphoma receiving R‐CHOP chemotherapy: a randomized clinical trial
  publication-title: JAMA
– volume: 42
  start-page: 139
  year: 2012
  end-page: 149
  article-title: Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B
  publication-title: Hepatol Res
– volume: 74
  start-page: 254
  year: 2005
  end-page: 258
  article-title: Hepatitis B virus reactivation and alemtuzumab therapy
  publication-title: Eur J Haematol
– volume: 52
  start-page: 176
  year: 2010
  end-page: 182
  article-title: Efficacy of entecavir in treatment‐naive patients with hepatitis B virus‐related decompensated cirrhosis
  publication-title: J Hepatol
– volume: 46
  start-page: 489
  year: 2016
  end-page: 491
  article-title: Reactivation of hepatitis B virus during interferon‐free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co‐infection
  publication-title: Hepatol Res
– volume: 18
  start-page: 77
  year: 2013
  end-page: 85
  article-title: Clonal analysis of the quasispecies of antiviral‐resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir
  publication-title: Antivir Ther
– volume: 8
  start-page: 869
  year: 2014
  end-page: 873
  article-title: Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
  publication-title: Drug Des Devel Ther
– volume: 109
  start-page: 908
  year: 1995
  end-page: 916
  article-title: Low‐dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus
  publication-title: Gastroenterology
– volume: 47
  start-page: 844
  year: 2008
  end-page: 853
  article-title: A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: a randomized trial
  publication-title: Hepatology
– volume: 65
  start-page: 852
  year: 2016
  end-page: 860
  article-title: Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir‐resistant chronic hepatitis B with multiple drug failure: results of a randomised trial
  publication-title: Gut
– volume: 30
  start-page: 189
  year: 2002
  end-page: 194
  article-title: Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft‐versus‐host disease
  publication-title: Bone Marrow Transplant
– volume: 78
  start-page: 341
  year: 2006
  end-page: 352
  article-title: Clinical and virological features of non‐breakthrough and severe exacerbation due to lamivudine‐resistant hepatitis B virus mutants
  publication-title: J Med Virol
– volume: 22
  start-page: 927
  year: 2004
  end-page: 934
  article-title: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s‐antigen seropositive cancer patients undergoing cytotoxic chemotherapy
  publication-title: J Clin Oncol
– volume: 51
  start-page: 3
  issue: Suppl 1
  year: 2008
  end-page: 6
  article-title: Hepatitis B core‐related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy
  publication-title: Intervirology
– volume: 18
  start-page: 2850
  year: 2012
  end-page: 2858
  article-title: DNA‐dependent activator of interferon‐regulatory factors inhibits hepatitis B virus replication
  publication-title: World J Gastroenterol
– volume: 36
  start-page: 186
  year: 2002
  end-page: 194
  article-title: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
  publication-title: Hepatology
– volume: 62
  start-page: 299
  year: 2000
  end-page: 307
  article-title: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors
  publication-title: J Med Virol
– volume: 33
  start-page: 301
  year: 2000
  end-page: 307
  article-title: Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
  publication-title: J Hepatol
– volume: 83
  start-page: 357
  year: 2009
  end-page: 364
  article-title: High risk of hepatitis B‐virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody‐positive patients
  publication-title: Eur J Haematol
– volume: 25
  start-page: 2037
  year: 1998
  end-page: 2038
  article-title: Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy
  publication-title: J Rheumatol
– volume: 135
  start-page: 759
  year: 2001
  end-page: 768
  article-title: Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus
  publication-title: Ann Intern Med
– volume: 106
  start-page: 1994
  year: 2011
  end-page: 2000
  article-title: Risk factors for early‐onset and late‐onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States
  publication-title: Am J Gastroenterol
– volume: 2
  start-page: 298
  year: 1988
  end-page: 302
  article-title: Long‐term follow‐up in a randomised controlled trial of recombinant alpha 2‐interferon in Chinese patients with chronic hepatitis B infection
  publication-title: Lancet
– volume: 85
  start-page: 597
  year: 2013
  end-page: 601
  article-title: Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti‐HBc negative patient
  publication-title: J Med Virol
– volume: 30
  start-page: 567
  year: 1999
  end-page: 572
  article-title: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
  publication-title: Hepatology
– volume: 21
  start-page: 16
  year: 2011
  end-page: 23
  article-title: Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients
  publication-title: Mod Rheumatol
– volume: 4
  start-page: 301
  year: 1984
  end-page: 306
  article-title: Determinants for hepatitis B e antigen clearance in chronic type B hepatitis
  publication-title: Liver
– volume: 148
  start-page: 519
  year: 2008
  end-page: 528
  article-title: Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
  publication-title: Ann Intern Med
– year: 2012
– volume: 47
  start-page: 1438
  year: 2017
  end-page: 1444
  article-title: Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all‐oral direct‐acting antivirals: Analysis of a Japanese prospective cohort
  publication-title: Hepatol Res
– volume: 88
  start-page: 4186
  year: 1991
  end-page: 4190
  article-title: Wild‐type and e antigen‐minus hepatitis B viruses and course of chronic hepatitis
  publication-title: Proc Natl Acad Sci U S A
– volume: 12
  start-page: 355
  year: 2007
  end-page: 362
  article-title: In vitro susceptibility of adefovir‐associated hepatitis B virus polymerase mutations to other antiviral agents
  publication-title: Antivir Ther
– volume: 48
  start-page: 3498
  year: 2004
  end-page: 3507
  article-title: Clinical emergence of entecavir‐resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
  publication-title: Antimicrob Agents Chemother
– volume: 32
  start-page: 162
  year: 2005
  end-page: 165
  article-title: HBV reactivation after kidney transplantation
  publication-title: J Clin Virol
– volume: 351
  start-page: 1521
  year: 2004
  end-page: 1531
  article-title: Lamivudine for patients with chronic hepatitis B and advanced liver disease
  publication-title: N Engl J Med
– volume: 49
  start-page: 3486
  year: 2013
  end-page: 3496
  article-title: Hepatitis B virus reactivation in B‐cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group
  publication-title: Eur J Cancer
– volume: 6
  start-page: 167
  year: 1986
  end-page: 172
  article-title: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B
  publication-title: Hepatology
– volume: 81
  start-page: 27
  year: 2009
  end-page: 33
  article-title: Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients
  publication-title: J Med Virol
– volume: 130
  start-page: 678
  year: 2006
  end-page: 686
  article-title: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
  publication-title: Gastroenterology
– volume: 2
  start-page: 877
  year: 1987
  end-page: 880
  article-title: Placebo‐controlled trial of recombinant alpha 2‐interferon in Chinese HBsAg‐carrier children
  publication-title: Lancet
– volume: 30
  start-page: 770
  year: 1999
  end-page: 774
  article-title: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group
  publication-title: Hepatology
– volume: 2
  start-page: 263
  year: 2008
  end-page: 283
  article-title: Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
  publication-title: Hepatol Int
– volume: 61
  start-page: 719
  year: 2015
  end-page: 729
  article-title: Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B‐cell lymphoma: a prospective observational study
  publication-title: Clin Infect Dis
– volume: 38
  start-page: 181
  year: 2011
  end-page: 182
  article-title: Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases
  publication-title: J Rheumatol
– volume: 36
  start-page: 133
  year: 2001
  end-page: 136
  article-title: Interferon therapy for flare‐up of hepatitis B virus infection after emergence of lamivudine‐induced YMDD motif mutant
  publication-title: J Gastroenterol
– volume: 29
  start-page: 428
  year: 2014
  end-page: 434
  article-title: Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment
  publication-title: J Gastroenterol Hepatol
– volume: 79
  start-page: 1811
  year: 2007
  end-page: 1817
  article-title: Successful treatment of an entecavir‐resistant hepatitis B virus variant
  publication-title: J Med Virol
– volume: 42
  start-page: 333
  year: 2012
  end-page: 339
  article-title: Risk of hepatitis B reactivation in patients treated with tumor necrosis factor‐alpha inhibitors
  publication-title: Hepatol Res
– volume: 121
  start-page: 274
  year: 1994
  end-page: 275
  article-title: Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation
  publication-title: Ann Intern Med
– volume: 94
  start-page: 744
  year: 1981
  end-page: 748
  article-title: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
  publication-title: Ann Intern Med
– volume: 94
  start-page: 1618
  year: 2009
  end-page: 1622
  article-title: Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report
  publication-title: Haematologica
– volume: 347
  start-page: 168
  year: 2002
  end-page: 174
  article-title: Hepatitis B e antigen and the risk of hepatocellular carcinoma
  publication-title: N Engl J Med
– volume: 118
  start-page: 191
  year: 1993
  end-page: 194
  article-title: The natural history of asymptomatic hepatitis B surface antigen carriers
  publication-title: Ann Intern Med
– ident: e_1_2_10_14_1
  doi: 10.1053/j.gastro.2013.12.028
– ident: e_1_2_10_48_1
  doi: 10.7326/0003-4819-118-3-199302010-00006
– ident: e_1_2_10_115_1
  doi: 10.1111/hepr.12117
– ident: e_1_2_10_117_1
  doi: 10.1002/hep.22106
– ident: e_1_2_10_101_1
  doi: 10.1053/j.gastro.2006.04.015
– ident: e_1_2_10_142_1
  doi: 10.1111/j.1872-034X.2012.00998.x
– ident: e_1_2_10_94_1
  doi: 10.2957/kanzo.50.38
– ident: e_1_2_10_13_1
– ident: e_1_2_10_139_1
  doi: 10.1200/JCO.2008.18.0182
– ident: e_1_2_10_137_1
  doi: 10.1179/102453309X385223
– ident: e_1_2_10_65_1
  doi: 10.1016/j.jhep.2009.12.036
– ident: e_1_2_10_61_1
  doi: 10.1016/0016-5085(95)90401-8
– ident: e_1_2_10_36_1
  doi: 10.1055/s-2006-939751
– ident: e_1_2_10_41_1
  doi: 10.1002/hep.20956
– ident: e_1_2_10_16_1
  doi: 10.1016/S2468-1253(16)30024-3
– ident: e_1_2_10_106_1
  doi: 10.1016/j.jcv.2011.06.020
– ident: e_1_2_10_165_1
  doi: 10.1002/hep.27950
– ident: e_1_2_10_18_1
  doi: 10.1016/j.jhep.2017.11.039
– ident: e_1_2_10_56_1
  doi: 10.1016/0168-8278(91)90031-6
– ident: e_1_2_10_5_1
  doi: 10.1007/s12072-008-9080-3
– volume: 58
  start-page: 649A
  year: 2013
  ident: e_1_2_10_12_1
  article-title: Seven years of treatment with tenofovir df for chronic hepatitis b virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance
  publication-title: Hepatology
– ident: e_1_2_10_27_1
  doi: 10.1016/j.jhep.2007.07.022
– ident: e_1_2_10_55_1
  doi: 10.1016/j.jhep.2011.11.030
– ident: e_1_2_10_143_1
  doi: 10.1053/j.gastro.2003.09.026
– ident: e_1_2_10_33_1
  doi: 10.1111/j.1600-0676.1984.tb00942.x
– ident: e_1_2_10_47_1
  doi: 10.3748/wjg.v18.i22.2850
– ident: e_1_2_10_164_1
  doi: 10.1111/jvh.12840
– ident: e_1_2_10_93_1
  doi: 10.1111/hepr.12108
– ident: e_1_2_10_149_1
  doi: 10.1136/annrheumdis-2016-209973
– ident: e_1_2_10_102_1
  doi: 10.1182/blood-2003-05-1403
– ident: e_1_2_10_7_1
  doi: 10.1111/hepr.12842
– ident: e_1_2_10_84_1
  doi: 10.1136/gutjnl-2014-308353
– ident: e_1_2_10_141_1
  doi: 10.1086/590968
– ident: e_1_2_10_82_1
  doi: 10.1002/jmv.20981
– ident: e_1_2_10_145_1
  doi: 10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0
– ident: e_1_2_10_4_1
  doi: 10.1016/j.jhep.2012.02.010
– ident: e_1_2_10_124_1
  doi: 10.1001/jama.2014.15704
– ident: e_1_2_10_92_1
  doi: 10.1111/j.1872-034X.2007.00094.x
– ident: e_1_2_10_100_1
  doi: 10.1016/j.jcv.2004.10.006
– ident: e_1_2_10_19_1
  doi: 10.1111/j.1872-034X.2011.00910.x
– ident: e_1_2_10_29_1
  doi: 10.1002/hep.1840070106
– ident: e_1_2_10_155_1
  doi: 10.3324/haematol.2009.008607
– ident: e_1_2_10_40_1
  doi: 10.1056/NEJMoa013215
– ident: e_1_2_10_78_1
  doi: 10.1016/j.jhep.2008.02.019
– ident: e_1_2_10_134_1
  doi: 10.1097/00007890-199809150-00012
– ident: e_1_2_10_51_1
  doi: 10.7326/0003-4819-135-9-200111060-00006
– ident: e_1_2_10_131_1
  doi: 10.1016/0016-5085(88)90623-3
– volume: 26
  start-page: 51
  year: 2018
  ident: e_1_2_10_152_1
  article-title: Reactivation of hepatitis B
  publication-title: Inflammation & Immunity [in Japanese]
– volume: 22
  start-page: 375
  year: 2004
  ident: e_1_2_10_109_1
  article-title: follow in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low‐dose methotrexate therapy for rheumatoid arthritis
  publication-title: Clin Exp Rheumatol
– volume: 14
  start-page: 39
  issue: 2
  year: 2000
  ident: e_1_2_10_126_1
  article-title: Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges
  publication-title: Clin Transplant
– ident: e_1_2_10_161_1
  doi: 10.1111/hepr.12578
– ident: e_1_2_10_127_1
  doi: 10.1002/hep.510280241
– ident: e_1_2_10_144_1
  doi: 10.1016/0016-5085(91)90599-G
– ident: e_1_2_10_57_1
  doi: 10.1016/S0168-8278(01)00266-5
– ident: e_1_2_10_23_1
  doi: 10.1016/S0140-6736(88)92355-0
– ident: e_1_2_10_120_1
  doi: 10.1016/j.transproceed.2010.05.127
– ident: e_1_2_10_85_1
  doi: 10.1177/135965350501000612
– ident: e_1_2_10_119_1
  doi: 10.7326/0003-4819-148-7-200804010-00008
– ident: e_1_2_10_58_1
  doi: 10.1053/jhep.2001.27834
– ident: e_1_2_10_6_1
  doi: 10.1111/hepr.12902
– ident: e_1_2_10_46_1
  doi: 10.1002/hep.21077
– ident: e_1_2_10_3_1
  doi: 10.1002/hep.23190
– ident: e_1_2_10_59_1
  doi: 10.1073/pnas.88.10.4186
– ident: e_1_2_10_2_1
  doi: 10.1111/hepr.12269
– ident: e_1_2_10_39_1
  doi: 10.1053/j.gastro.2005.11.016
– ident: e_1_2_10_90_1
  doi: 10.1002/jmv.21339
– ident: e_1_2_10_28_1
  doi: 10.1016/S0016-5085(83)80114-0
– ident: e_1_2_10_63_1
  doi: 10.1056/NEJM199008023230503
– ident: e_1_2_10_9_1
  doi: 10.1136/gut.2010.223206
– ident: e_1_2_10_77_1
  doi: 10.1053/j.gastro.2009.08.063
– ident: e_1_2_10_110_1
  doi: 10.1002/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q
– ident: e_1_2_10_150_1
  doi: 10.1007/s00535-016-1168-2
– ident: e_1_2_10_79_1
  doi: 10.1136/gutjnl-2014-308435
– ident: e_1_2_10_32_1
  doi: 10.1002/hep.1840060203
– ident: e_1_2_10_68_1
  doi: 10.1002/hep.510310130
– ident: e_1_2_10_132_1
  doi: 10.1093/ndt/16.11.2222
– ident: e_1_2_10_67_1
  doi: 10.1053/gast.2002.35352
– ident: e_1_2_10_114_1
  doi: 10.1111/hepr.12513
– ident: e_1_2_10_70_1
  doi: 10.1016/j.jhep.2009.11.007
– ident: e_1_2_10_158_1
  doi: 10.1086/653209
– ident: e_1_2_10_74_1
  doi: 10.1002/jmv.20546
– ident: e_1_2_10_26_1
  doi: 10.1007/s12072-008-9068-z
– ident: e_1_2_10_105_1
  doi: 10.1016/j.jhep.2008.07.040
– ident: e_1_2_10_17_1
– ident: e_1_2_10_52_1
  doi: 10.1002/hep.22878
– ident: e_1_2_10_62_1
  doi: 10.1002/hep.21723
– ident: e_1_2_10_160_1
  doi: 10.1016/j.jcv.2016.02.026
– ident: e_1_2_10_133_1
  doi: 10.1038/sj.bmt.1700744
– ident: e_1_2_10_87_1
  doi: 10.2147/DDDT.S65349
– ident: e_1_2_10_49_1
  doi: 10.7326/0003-4819-94-6-744
– ident: e_1_2_10_151_1
  doi: 10.3109/s10165-010-0337-z
– volume: 40
  start-page: 1561
  year: 2013
  ident: e_1_2_10_154_1
  article-title: A case of hepatitis B virus reactivation in a patient with prior resolved hepatitis B infection during bevacizumab plus FOLFIRI treatment
  publication-title: Gan To Kagaku Ryoho
– ident: e_1_2_10_159_1
  doi: 10.1093/cid/civ474
– ident: e_1_2_10_107_1
  doi: 10.3899/jrheum.100692
– ident: e_1_2_10_122_1
  doi: 10.1007/s00535-010-0367-5
– ident: e_1_2_10_147_1
  doi: 10.1136/ard.2005.043257
– ident: e_1_2_10_140_1
  doi: 10.1002/hep.26718
– ident: e_1_2_10_148_1
  doi: 10.1111/j.1872-034X.2011.00937.x
– ident: e_1_2_10_135_1
  doi: 10.1038/sj.bmt.1703614
– ident: e_1_2_10_24_1
  doi: 10.1016/0016-5085(92)90337-X
– ident: e_1_2_10_130_1
  doi: 10.1002/hep.1840030309
– ident: e_1_2_10_129_1
  doi: 10.1016/0016-5085(91)70034-U
– ident: e_1_2_10_42_1
  doi: 10.1093/jnci/dji043
– ident: e_1_2_10_121_1
  doi: 10.1182/blood-2018-10-878892
– ident: e_1_2_10_125_1
  doi: 10.1097/00007890-199802270-00007
– ident: e_1_2_10_64_1
  doi: 10.1056/NEJMoa033364
– ident: e_1_2_10_97_1
  doi: 10.1182/blood-2018-04-848044
– ident: e_1_2_10_44_1
  doi: 10.3748/wjg.v18.i21.2661
– ident: e_1_2_10_10_1
  doi: 10.1111/jgh.12499
– ident: e_1_2_10_60_1
  doi: 10.1016/0016-5085(93)90281-G
– ident: e_1_2_10_156_1
  doi: 10.3960/jslrt.52.67
– ident: e_1_2_10_111_1
  doi: 10.1016/0016-5085(94)90557-6
– ident: e_1_2_10_11_1
  doi: 10.1517/14740331003627458
– ident: e_1_2_10_128_1
  doi: 10.1111/j.1600-6143.2006.01542.x
– ident: e_1_2_10_43_1
  doi: 10.1016/j.jhep.2006.08.021
– ident: e_1_2_10_112_1
  doi: 10.7326/0003-4819-121-4-199408150-00007
– ident: e_1_2_10_96_1
  doi: 10.1093/cid/civ344
– ident: e_1_2_10_136_1
  doi: 10.1111/j.1600-0609.2009.01291.x
– ident: e_1_2_10_99_1
– ident: e_1_2_10_30_1
  doi: 10.1016/0168-8278(90)90069-4
– ident: e_1_2_10_75_1
  doi: 10.1007/s005350170143
– ident: e_1_2_10_73_1
  doi: 10.1002/hep.510300221
– ident: e_1_2_10_80_1
  doi: 10.1128/AAC.48.9.3498-3507.2004
– ident: e_1_2_10_37_1
  doi: 10.1001/jama.295.1.65
– ident: e_1_2_10_88_1
  doi: 10.1016/j.hepres.2006.08.005
– ident: e_1_2_10_76_1
  doi: 10.1007/s005350200155
– ident: e_1_2_10_38_1
  doi: 10.1023/B:CACO.0000007984.79987.ec
– ident: e_1_2_10_116_1
  doi: 10.1200/JCO.2004.05.161
– ident: e_1_2_10_103_1
  doi: 10.1056/NEJMoa1007644
– ident: e_1_2_10_89_1
  doi: 10.1159/000122592
– ident: e_1_2_10_25_1
  doi: 10.1053/jhep.2002.34294
– ident: e_1_2_10_83_1
  doi: 10.3851/IMP2294
– ident: e_1_2_10_22_1
  doi: 10.1016/S0140-6736(87)91371-7
– ident: e_1_2_10_146_1
  doi: 10.1038/sj.bjc.6601699
– ident: e_1_2_10_45_1
  doi: 10.1038/ajg.2011.302
– ident: e_1_2_10_31_1
  doi: 10.1016/0016-5085(87)90613-5
– ident: e_1_2_10_163_1
  doi: 10.1111/liv.13496
– ident: e_1_2_10_72_1
  doi: 10.1002/hep.23346
– ident: e_1_2_10_66_1
  doi: 10.1002/hep.23785
– ident: e_1_2_10_91_1
  doi: 10.1128/JCM.00366-07
– volume: 25
  start-page: 2037
  year: 1998
  ident: e_1_2_10_108_1
  article-title: Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy
  publication-title: J Rheumatol
– ident: e_1_2_10_50_1
  doi: 10.1053/jhep.2002.33638
– ident: e_1_2_10_8_1
  doi: 10.1002/hep.23246
– volume: 78
  start-page: 155
  year: 1991
  ident: e_1_2_10_21_1
  article-title: Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children
  publication-title: Q J Med
– volume: 12
  start-page: 355
  year: 2007
  ident: e_1_2_10_86_1
  article-title: In vitro susceptibility of adefovir‐associated hepatitis B virus polymerase mutations to other antiviral agents
  publication-title: Antivir Ther
  doi: 10.1177/135965350701200309
– ident: e_1_2_10_138_1
  doi: 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
– ident: e_1_2_10_53_1
  doi: 10.1016/S0168-8278(02)00004-1
– ident: e_1_2_10_113_1
  doi: 10.1097/BOR.0b013e3282f05b63
– ident: e_1_2_10_153_1
  doi: 10.1111/j.1600-0609.2004.00375.x
– ident: e_1_2_10_123_1
  doi: 10.1016/j.ejca.2013.07.006
– ident: e_1_2_10_157_1
  doi: 10.3748/wjg.v20.i11.2955
– ident: e_1_2_10_20_1
  doi: 10.1002/hep.510300313
– ident: e_1_2_10_34_1
  doi: 10.1016/j.cld.2010.05.007
– ident: e_1_2_10_15_1
  doi: 10.1016/S2468-1253(16)30107-8
– ident: e_1_2_10_35_1
  doi: 10.1016/j.jhep.2007.11.011
– ident: e_1_2_10_95_1
– ident: e_1_2_10_98_1
– ident: e_1_2_10_104_1
  doi: 10.1002/jmv.23513
– ident: e_1_2_10_81_1
  doi: 10.3851/IMP1304
– ident: e_1_2_10_162_1
  doi: 10.1111/hepr.12919
– ident: e_1_2_10_69_1
  doi: 10.1016/S0168-8278(00)80371-2
– ident: e_1_2_10_54_1
  doi: 10.1016/0016-5085(84)90406-2
– ident: e_1_2_10_71_1
  doi: 10.1002/hep.24361
– ident: e_1_2_10_118_1
  doi: 10.1053/jhep.2002.35068
SSID ssj0017024
Score 2.5525327
Snippet The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the...
SourceID proquest
crossref
wiley
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 892
SubjectTerms antiviral treatment
drug resistance
Hepatitis B
hepatocellular carcinoma
Hepatology
Management
Tenofovir
tenofovir alafenamide
tenofovir disoproxil fumarate
Title Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhepr.13504
https://www.proquest.com/docview/2435486777
https://www.proquest.com/docview/2395608965
Volume 50
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bSsNAEB2kgvjiXaxWWdEXhUhz2SQVX1q1VkERUfFFQrLZRVHS0jYP-jV-i1_mzHaTqoigb4FMyGV3MudsTs4AbCep4gqJhVaqWR5HzhqrMLFiX9o0Z4RIaB3y_MLv3Hhnd_xuAg6Kf2FG_hDlghtlhn5fU4LHyeBTkj_IXp-6NmgzUBJrESK6Kr2j7KBuOtqGvuW7nm-8SUnGMz70azUaQ8zPQFVXmvYs3BfXOBKYPO3lw2RPvH6zb_zvTczBjIGgrDmaM_MwIbMFmDo3H9kXQZ1hAc2Y0XOyrmIdrFm6z-0LO8nJF4u08gzhLkP4yMYKmjKWjJLe31rs9rGfD9ipEXxl-wyBQIPlPVpmWIKb9vH1Yccy7RgsQX_DWY5CNBa6SHBkkCrpuFjWYqzwkkvucmTowhHCliFXXhoEcSrxPevZCZfKd20lPXcZKlk3kyvAQpWKkPseYtPEq7uSSFfYIDLXQEwiRRV2imGJhPEqp5YZz1HBWejBRfrBVWGrjO2NHDp-jKoVoxuZLB1EDmJFchwMgipslrsxv-ijSZzJbo4xLjHIsOHzKuzqofzlLFHn-PJKb63-JXgNph2i8VpXWIPKsJ_LdcQ6w2QDJputo1Z7Q8_tD-s8-wA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtNAEB6VIgGX8luR0sIi4ACSq9jetR0kDkBbnLapUNVWvbn2elagVk6UxELlaXgBXoIH4Jk6s1k7BSEkDj1wi-RR4nhnZr8Zf_sNwPOiNMpQYWGZap5UVLPmJim8PEKffUbrgvuQg70oPZTbx-p4Ab43Z2Fm-hBtw40jw-ZrDnBuSF-K8k84GvPYhq50nModPP9CFdvkTX-DlvdFEGxtHrxPPTdUwNN8pssLDGGKJCSYjnFpMAgpOee0T6FCFSqqM3WgtY-JMrKM47xEyhbSLxSaKPQNypC-9xpc5xHiLNW_sd-qVflx183QTSIvCmXk1FCZODS_11_3vzmovQyN7d62dRt-Nk9lRmk5Xa-nxbr--ptg5H_z2O7AkkPZ4u0sLO7CAlb34MbA8Qjug9kmjFAJR1kVQyNS2pbtKN9z8aFm6S8-DiAI0QtCyGJOEmptWQvqx7d34ujzuJ6IvuO0Va8FYZ2eqEfcSXkAh1fyL5dhsRpW-BBEYkqdqEgS_C5kN0SuK5Me16s9gl2oO_Cy8YNMOzl2ngpyljVlGS9UZheqA89a29FMhOSPVquNO2UuEU2ygOAwiyrGcQeetpcphfB7obzCYU02IRfJSS9SHXhlfecvv5Klmx_37aeVfzF-AjfTg8Futtvf23kEtwLuWlga5SosTsc1rhG0mxaPbUAJOLlqV7wA81dXCg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtNAEB6VIlVc-EcECiwCDiC5iu3dtY3EAUhD0tKqqijqzdjrWYFATpTEQuVpeACegjvvxMxm7RSEkDj0wM2SR_7bmdlv1t9-A_CwrKyyVFg4plogFdWshU3LoNAYss8YU_I65N6-Hh3JnWN1vAbf2r0wS32IbsGNI8Plaw7waWVPBfl7nM64a0NfekrlLp58poJt_mw8oNF9FEXD7TcvR4HvKRAY3tIVRJYgRRoTSsekshjFlJsLmqZQoYoVlZkmMibEVFlZJUlRISULGZYKrY5DizKm656D81L3M24UMTjsxKrCpO9b6KY60LHUXgyVeUOrZ_11-lth2tPI2E1tw0vwo_0oS0bLx61mUW6ZL7_pRf4vX-0yXPQYWzxfBsUVWMP6KmzseRbBNbA7hBBq4QmrYmLFiCZl18j3RLxqWPiLNwMIwvOC8LFYUYQ6W1aC-v71hXj7YdbMxdgz2uqngpBOJpopr6Nch6MzecsbsF5ParwJIrWVSZWWBL5L2Y-Rq8o042o1I9CFpgePWzfIjRdj554gn_K2KOOByt1A9eBBZztdSpD80Wqz9abcp6F5HhEYZknFJOnB_e40JRD-K1TUOGnIJuYSOc206sET5zp_uUs-2j44dEe3_sX4HmwcDIb56_H-7m24EPGSheNQbsL6YtbgHcJ1i_KuCycB787aE38Ce3xVuQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Japan+Society+of+Hepatology+Guidelines+for+the+Management+of+Hepatitis%C2%A0B+Virus+Infection%3A+2019+update&rft.jtitle=Hepatology+research&rft.date=2020-08-01&rft.issn=1386-6346&rft.eissn=1872-034X&rft.volume=50&rft.issue=8&rft.spage=892&rft.epage=923&rft_id=info:doi/10.1111%2Fhepr.13504&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_hepr_13504
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6346&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6346&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6346&client=summon